Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-be…
FAIL · Does not pass the screen
9.45 USD
Price as of 5 Nov 2026Daily close, not a live quote
Screened 2026-11-05 · the tape above runs as of 20:03 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price9.45 USD at the 5 Nov 2026 close
Our value readUndervalued vs our fair value, as of 5 Nov 2026
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price9.45 USD
Fair value21.20
Ethical score10.0/100
Value readUndervaluedas of 5 Nov 2026
Our investment reviews on this name
2026-10-17Read Markdown11.23-15.9% to today ✓Accumulation gives way to Markdown
2026-10-02Read Accumulation11.48-17.7% to today Markup gives way to Accumulation after an 11% rise in 4 weeks
2026-09-03Read Markup10.30-8.3% to today Distribution gives way to Markup with volume flow in agreement
2026-07-02Read Distribution10.30-8.3% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Keros Therapeutics, Inc. holds its Markdown at $9.45. The statistical read favours the buyers, held for 133 days.
As held on the ledger · 2026-11-05
Phase
Markdown · caution
Quantitative state
The statistical read favours the buyers, held for 133 days
Price at the screen
$9.45
Valuation
4.84 trailing · -2.36 forward price to earnings
Values screen
FAIL· score 10.0
The Workings
Five Screens, Shown in Full
Does not pass. Cash ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
7.12%
Below 33%
Interest-bearing debt is just 7.1% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
121.14%
Below 33%
Interest-bearing cash and securities are 121.1% of assets, above the one-third limit.
Fail
Receivables
0.00%
Below 49%
Money owed to the company is 0.0% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Keros Therapeutics,'s business is fine, but its cash and interest-bearing securities are about 121% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-05. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when KROS's ethical verdict changes
Today KROS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Undervalued vs our fair value, as of 5 Nov 2026: it trades at roughly a 49% discount to our $21.20 fair value.
Fair value range in USD, drawn from the 2026-11-05 screen. The gold marker is the market price at the same screen. A 55.4% discount to the base estimate.
Where our models see it going: fair-value estimate $21.20, with a range of $16.00 to $21.66, dated to the 2026-11-05 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it stands out
Trading at -2.4x forward earnings, with minimal debt. That is a 49% discount to our $21.20 fair value: the market is pricing it cautiously while the fundamentals argue otherwise. 5 analysts rate it Buy with a $21.20 average target, about 124% above the screened price.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
KROS trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-31Markdown$11.28+0.4%Entry 9
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 0.4% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
2026-10-24Markdown$11.23+0.0%Entry 8
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
2026-10-17Markdown · changed$11.23-2.2%Entry 7
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 11.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
2026-09-03Markup · changed$10.30+0.0%Entry 5
The framework has shifted from distribution to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
2026-08-04Distribution$10.30+0.0%Entry 4
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
2026-07-18Distribution$10.30+0.0%Entry 3
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 25%. The street (6 analysts) rates it buy, with a mean price target of $22.
2026-07-03Distribution$10.30+0.0%Entry 2
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$10.30Entry 1
Our analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · KROS
Date
Insider
Title
Type
Shares
Value
2026-05-15
BIENAIME JEAN-JACQUES
Director
1,000
$10,580
2026-04-15
BIENAIME JEAN-JACQUES
Director
1,000
$11,700
2026-04-02
SEEHRA JASBIR
Chief Executive Officer
55,000
$16,500
2026-03-09
BIENAIME JEAN-JACQUES
Director
2,000
$22,420
2026-03-09
NEWTON CHARLES W.
Director
13,215
·
2026-02-19
SEEHRA JASBIR
Chief Executive Officer
7,015
$113,433
2026-02-18
LERNER LORENA RAQUEL PH.D.
Officer
3,873
$63,324
2026-02-18
CHO ESTHER
General Counsel
4,745
$77,581
2026-02-18
REGNANTE KEITH C
Chief Financial Officer
4,739
$77,483
2025-10-15
ADAR1 CAPITAL MANAGEMENT LLC
Beneficial Owner of more than 10% of a Class of Security